Adrenocortical carcinoma - towards genomics guided clinical care.

摘要: Adrenocortical carcinoma (ACC) is an aggressive and rare neoplasm that originates in the cortex of adrenal gland. The disease associated with heterogeneous but mostly poor outcomes lacks effective pharmaceutical treatment options. Multi-omics studies have defined landscape molecular alterations ACC. Specific signatures can be detected body fluids, potentially enabling improved diagnostic applications for patients tumours. Importantly, pan-molecular data sets further reveal a spectrum within ACC, three major subgroups different outcomes. These new value as prognostic biomarkers. Research has revealed p53-RB WNT-β-catenin pathways are common drivers However, these remain difficult to target by therapeutic interventions. Instead, unique characteristic ACC steroidogenic differentiation, which emerged potential target, several agents undergoing preclinical or clinical investigations. Finally, large proportion tumours genetic profiles promising responsiveness other cancers. All opportunities now await translation from laboratory into setting, thereby offering real survival increased quality life this serious condition.